Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
73.00    -0.50 (-0.68%)
Bid:
72.00
Ask:
74.00
Spread: 2.00 (2.778%)
Market Cap: £342.04m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Sch 1 - Readybuy PLC

21 Jul 2006 10:15

AIM21 July 2006 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME:Readybuy plc COMPANY ADDRESS:Television House, 10-12 Mount Street, Manchester COMPANY POSTCODE:M2 5NT COUNTRY OF INCORPORATION:England and Wales COMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED INACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES:Since the Readybuy group's trading activities were terminated in July 2005, the directors of Readybuy have beenexploring the future options available to the Company. The Company's investing strategy is to acquire a companyinvolved in developing enabling technologies, particularly in the defence and bio-chemistry sectors. The Boardbelieves that the proposed acquisition of Avacta meets this investment strategy. Avacta was spun-out from the University of Leeds in January 2004 by its current management team as a biophysicscompany, with the aim of combining the disciplines of physics and biology to develop innovative technologies toaddress needs in the homeland security, pharmaceutical and clinical diagnostic markets. Avacta has two core activities: the development of detection technology platforms designed to meet the needs ofits target markets; and the provision of analytical services relating to the chemical and physical analysis ofmaterials to a range of companies, principally in the pharmaceutical, healthcare and personal care sectors. DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to whichit seeks admission and the number and type to be held as treasury shares):644,857,446 ordinary shares of 0.1p each on First Admission 24,469,898 ordinary shares of 0.1p each on Second AdmissionCAPITAL TO BE RAISED ON ADMISSION:£1,012,500 before expenses, by means of a placing of 45,000,000 ordinary shares of 0.1p each at 2.25p per share FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS:Directors: Daron Ross Lee (non-executive Chairman) Professor David Alastair Maclaughlin Smith (non-executive director and proposed Chief Executive followingAdmission) Proposed Directors: Dr. Gwynfor Owen Humphreys (proposed non-executive Chairman)Dr. Simon Webster (proposed Chief Scientific Officer)Dr. Kurt Justin Baldwin (proposed Chief Technology Officer)Timothy James Sykes (proposed Chief Financial Officer and proposed Company Secretary)Professor Anthony William Robards (proposed non-executive director)Alan John Aubrey (propose non-executive director) PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITALBEFORE AND AFTER ADMISSION:Before: Robert Quested (29.76%)Christopher Potts (16.96%)Stephen James (16.09%)Robert Quested, Christopher Potts and Stephen James are also interested in warrants to subscribe for 18,500,000;10,500,000; and 10,000,000 Ordinary Shares respectively. On Admission: Robert Quested (8.93%)Christopher Potts (3.15%)Stephen James (2.99%) The members of the Existing Concert Party, as at the date of this document, together hold 83.71% of the issuedshare capital of the Company, and will, immediately following the Placing and Admission hold 19.84 % thereof.The members of the New Concert Party (being the vendors of Avacta), as at the date of this document, togetherhold 0.96% of the issued share capital of the Company, and will, immediately following the Placing and Admissionhold 74.88% thereof. NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:None ANTICIPATED ACCOUNTING REFERENCE DATE:30 April EXPECTED ADMISSION DATE:8 August 2006 (First Admission)9 August 2006 (Second Admission) NAME AND ADDRESS OF NOMINATED ADVISER:WH Ireland Limited11 St James's SquareManchesterM2 6WH NAME AND ADDRESS OF BROKER:WH Ireland Limited11 St James's SquareManchesterM2 6WH DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENTTHAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:Copies of the admission document containing full details about the applicant and the admission of its securitieswill be available free of charge to the public until at least one month after admission at the offices of:- WH Ireland Limited11 St James's SquareManchesterM2 6WH DATE OF NOTIFICATION:21 July 2006 NEW/ UPDATE (see note):New This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th May 20157:01 amRNSIssue of Equity
28th Apr 20157:00 amRNSHalf Yearly Report
8th Apr 20157:00 amRNSNotice of Results
23rd Mar 20157:00 amRNSDrug discovery partnership
23rd Mar 20157:00 amRNSIssue of Equity
12th Feb 20157:00 amRNSSale of Optim Trade and Assets
9th Feb 20157:00 amRNSAffimer Development Contract with Protatonce
23rd Jan 20152:31 pmRNSResult of AGM
23rd Jan 20157:00 amRNSTrading Statement
16th Jan 20157:00 amRNSCommercial Partnership in the Agri-bio Market
6th Jan 20157:00 amRNSIssue of Equity
22nd Dec 20147:00 amRNSPosting of Annual Report & Accounts and AGM Notice
16th Oct 20147:00 amRNSFinal Results
30th Sep 20147:00 amRNSAffimer On-line Catalogue Launch
29th Sep 20147:00 amRNSInvestor Briefing
22nd Sep 20147:00 amRNSAppointment of a Senior Executive
4th Aug 20147:00 amRNSNew OPTIM Software and Hardware
1st Aug 20147:00 amRNSPre Close Trading Update
15th Jul 20147:00 amRNSMajor Japanese Distributor Signed
13th Jun 201411:04 amRNSHolding(s) in Company
2nd Jun 20141:04 pmRNSHolding(s) in Company
2nd Jun 20147:00 amRNSAvacta Secures Funding Award
30th May 20144:37 pmRNSHolding(s) in Company
30th May 20142:52 pmRNSHolding(s) in Company
29th May 20144:21 pmRNSHolding(s) in Company
28th May 20147:00 amRNSAvacta Life Sciences Exhibits Affimers at PEGS
23rd May 201412:53 pmRNSResult of General Meeting
21st May 20145:36 pmRNSHolding(s) in Company
14th May 20147:00 amRNSIssue of Equity
9th May 20144:19 pmRNSDirector's dealing
9th May 20147:00 amRNSAvacta Announce Collaboration with UbiQ Bio BV
7th May 20147:00 amRNSConditional Placing
23rd Apr 20147:00 amRNSInterim Results
14th Apr 20147:00 amRNSAvacta Launch Pancreatitis Test for Dogs
20th Mar 20147:00 amRNSAffimers : Technical and Commercial Update
11th Mar 20147:00 amRNSNotice of Interim Results
24th Feb 20147:00 amRNSDirectors Dealings
5th Feb 20147:00 amRNSNew Board Appointment
4th Feb 20149:29 amRNSHolding(s) in Company
3rd Feb 20147:00 amRNSAvacta Initiates Collaboration with University
28th Jan 20147:00 amRNSAvacta Life Sciences Launches Affimers Web Site
24th Jan 20142:57 pmRNSResult of AGM
24th Jan 20147:00 amRNSAGM Statement
20th Jan 20147:00 amRNSIssue of Equity
13th Jan 20147:00 amRNSInvestor teach-in
23rd Dec 20132:59 pmRNSNotice of AGM and Report and Accounts
23rd Dec 20137:00 amRNSBoard Appointment
27th Nov 201310:01 amRNSNew Canine Lymphoma Blood Test Launched
1st Nov 20137:00 amRNSIssue of Equity
24th Oct 20137:00 amRNSPreliminary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.